Staff
Milan Patel leads the strategic vision, financial health and global growth of PathogenDx, a Scottsdale, AZ based company which provides disruptive DNA-based pathogen testing technology and solutions for the cannabis, botanical, food and agricultural industries.
Previously, Mr. Patel spent over 25 years working with large public, small private and entrepreneurial companies in numerous fields from the life sciences, to biotechnology, to government services and the automotive industry. Milan served as COO/CFO of GMSbiotech. He also was CFO of 2020 Company, LLC, a leading premier professional services firm that delivered business and technology solutions to the government, in the areas of health, education and science.
Mr. Patel also worked at Intel Corporation in Sales & Marketing, Finance and Manufacturing. He has extensive experience in corporate finance, mergers and acquisitions, business strategy and planning, infrastructure and organizational development, and controls, compliance and audit and has led several company exits.
Milan earned his BS in Electrical and Electronics Engineering from the University of Detroit Mercy; a MS in Biomedical/Medical Engineering, University of Michigan; and a MBA in Finance and Marketing, University of Detroit Mercy.
Title: CEO
Company: PathogenDx
Years at current company: since founding (Almost 5 years)
GMR Executive Spotlight Q&A:
Most successful professional accomplishment before cannabis: Milan spent over 25 years working with large public, small private and entrepreneurial companies in numerous fields, from the life sciences to biotechnology to government services and even the automotive industry. He previously served as COO/CFO of GMSbiotech and CFO of 2020 Company, LLC, a leading premier professional services firm that delivered business and technology solutions to the government in the areas of health, education and science. Has exited to two companies in Federal Government and Healthcare IT.
Company Mission: Headquartered in Scottsdale, Arizona, PathogenDx’s mission is to become the new standard in DNA-based testing through widespread adoption of its advanced microarray testing platform for the cannabis, hemp, agriculture, food and beverage industries. PathogenDx’s technology can rapidly identify and detect up to 50 pathogens all in a single test, in 6 hours providing triplicate data per analyte for certainty in results with a simple and easy process. The company’s DNA-testing products – DetectX™, QuantX™, and EnviroX™– are disrupting the century-old practice of petri-dish testing to identify, detect and quantify pathogens like E. Coli, Salmonella and Aspergillus and a host of other bacterial and fungal microbial organisms in a fraction of the time, cost and labor to conventional methods that have been used by industries worldwide in microbial/pathogen testing. This technology will help growing businesses deliver safer products and healthier lives, while preventing millions of dollars in losses from contaminated or spoiled crops.
Company’s most successful achievement: We’ve been successful in commercializing our disruptive, game-changing technology in the form of three separate products into cannabis to become the predominant microbial testing technology in the cannabis sector.
Has the company raised any capital (yes or no): yes
If so, how much?: PathogenDx recently announced that they raised $7.5M in their Series B funding round, led by Cresco Capital Partners and joined by Altitude Investment Management, Arcadian Investment Partners, Panther Opportunity Fund, Salveo Capital, Halley Venture Partners and Flatiron Venture Partners.
Previously, PathogenDx raised $3.4M in a Convertible Note Round.
Any plans on raising capital in the future? Yes – we plan to raise more capital in order to scale and grow into other markets
Most important company 5 year goal: PathogenDx aims to become the emerging microbial/pathogen technology of choice in Cannabis, Hemp, Food, Environmental, Agriculture and Healthcare – and ultimately become the gold-standard in microbial testing.
